Entry |
|
Name |
Elosulfase alfa (USAN); Elosulfase alfa (genetical recombination) (JAN); Vimizim (TN) |
Product |
|
Formula |
C5020H7588N1364O1418S34
|
Exact mass |
110755.4086
|
Mol weight |
110824.4607
|
Sequence |
APQPPNILLL LMDDMGWGDL GVYGEPSRET PLCSPSRAAL LTGRLPIRNG FYTTNAHARN LLKKAGYVSK IVGKWHLGHR PQFHPLKHGF NIPVYRDWEM VGRYYEEFPI NLKTGEANLT FLYWAVDATH APVYASKPFL GTSQRGRYGD VADNTFVFFT SDNGAALISA PEQGGSNGPF PGHVTAGQVS HQLGSIMDLF TTSLALAGLT LMDRPIFYYR GDTLMAATLG QHKAHFWTWT VTTHNLEDHT KLPLIFHLGR DPGERFPLSF EALVPAQPQL NVCNWAVMNW APPGCEKLGK PNLDRMAAEG LLFPNFYSAN AYTPQEIVGG IPDSEQLLPE DEWFGSPNCH FGPYDNKARP QIYLQEALDF IKRQARHHPF AVREIDDSIG KILELLQDLH LCGKQTTFEG GMREPALAWW PPSDRAIDGL NLLPTLLQGR NSWENFRQGI DFCPGQNVSG ASAEYQEALS RITSVVQQHQ CLTPPESIPK KCLWSH (Disulfide bridge: 139-139' 282-393 282'-393' 463-492 463'-492' 475-481 475'-481') |
Type |
Peptide |
Remark |
Therapeutic category: | 3959 |
|
Efficacy |
Lysosomal storage disease treatment, Enzyme replacement (N-acetylgalactosamine-6-sulfatase) |
Disease |
Mucopolysaccharidosis type IVA [DS: H00123] |
Comment |
Enzyme replacement therapy product
|
Target |
|
Network |
N10010 | Replacement of deficient GALNS |
|
Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
A ALIMENTARY TRACT AND METABOLISM
A16 OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
A16A OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
A16AB Enzymes
A16AB12 Elosulfasealfa
D10333 Elosulfase alfa (USAN) <JP/US>
USP drug classification [BR:br08302]
Genetic, Enzyme, or Protein Disorder: Replacement, Modifiers, Treatment
Elosulfase Alfa
D10333 Elosulfase alfa (USAN)
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
39 Other agents affecting metabolism
395 Enzyme preparations
3959 Others
D10333 Elosulfase alfa (USAN); Elosulfase alfa (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
Enzymes
Hydrolases (EC3)
Sulfatases
GALNS* [HSA_VAR:2588v1]
D10333 Elosulfase alfa (USAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D10333
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D10333
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D10333
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10333
Pharmacogenomic biomarkers [br08341.html]
Germline mutations in genetic disorder treatments
D10333
|
Other DBs |
|
LinkDB |
|